Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 18/20 | 0.74 |
| ▸ | RXRG | P48443 | 14/20 | 0.74 |
| ▸ | RXRB | P28702 | 13/20 | 0.74 |
| ▸ | RARB | P10826 | 11/20 | 0.74 |
| ▸ | RARG | P13631 | 9/20 | 0.74 |
| ▸ | RARA | P10276 | 7/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7219497 | 1.00 | RXRA (0.74) | RXRARXRGRXRBRARBRARG | |
| SCHEMBL10399347 | 0.87 | RARG (0.72) | RXRARXRGRXRBRARBRARG | |
| SCHEMBL10399345 | 0.87 | RARG (0.72) | RXRARXRGRXRBRARBRARG | |
| SCHEMBL6427528 | 0.87 | RXRA (0.56) | RXRARXRGRXRBRARBRARG | |
| SCHEMBL3688710 | 0.85 | RXRA (1.00) | RXRARXRGRXRBRARBRARG | |
| SCHEMBL3688709 | 0.85 | RXRA (1.00) | RXRARXRGRXRBRARBRARG | |
| SCHEMBL3688713 | 0.85 | RXRA (1.00) | RXRARXRGRXRBRARBRARG | |
| SCHEMBL10399194 | 0.83 | RARB (0.51) | RXRARXRGRXRBRARBRARG | |
| SCHEMBL10399193 | 0.83 | RARB (0.51) | RXRARXRGRXRBRARBRARG | |
| SCHEMBL7418443 | 0.82 | RXRA (0.71) | RXRARXRGRXRBRARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624188-B1 | Administered to treat or prevent one or more of the diseases and conditions selected from the group consisting of dermatoses, atherosclerosis and restenosis resulting from neointimal hyperproliferation, non-malignant and | ALLERGAN, INC. | 2003-09-23 | — | — | US | disclosed |
| EP-0688213-B1 | TREATMENT OF TUMORS WITH COMPOUNDS HAVING RXR RETINOID RECEPTOR AGONIST ACTIVITY | ALLERGAN INC (US) | 2001-12-12 | — | — | EP | disclosed |
| EP-0909560-A2 | Treatment o tumors with compounds having RXR retinoid receptor agoinst activity | ALLERGAN, INC. (US) | 1999-04-21 | — | — | EP | disclosed |
| US-5399586-A | Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity | ALLERGAN, INC. (US) | 1995-03-21 | — | — | US | disclosed |
| US-5324840-A | Skin disorders | ALLERGAN, INC. (US) | 1994-06-28 | — | — | US | disclosed |